featured
2021 Top Story in Metastatic Breast Cancer: CDK4/6 Inhibitors - Standing the Test of Time
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Mouabbi JA, Osborne CK, Schiff R, et al. Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer. Breast Cancer Res Treat. 2021;190(2):189-201.
- Management of HR+, HER2− Metastatic Breast Cancer. PracticeUpdate. Accessed December 1, 2021.
- Turner NC, Salmon DJ, Ro J, et.al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018;379(20):1926-1936.
- Cristofanilli M. ASCO 2021: Addition of Palbociclib to Fulvestrant Attains Overall Survival Benefit in Advanced Breast Cancer With Update of PALOMA-3. PracticeUpdate. Accessed December 1, 2021.
- Salmon DJ. ASCO 2021: Updated Results of MONALEESA-3 Show Sustained Overall Survival Benefits With Ribociclib in Advanced Breast Cancer. PracticeUpdate. Accessed December 1, 2021.
- Hortobagyi G. ESMO 2021: MONALEESA-2 Update Confirms Overall Survival Benefit With Addition of Ribociclib to Letrozole in Advanced Breast Cancer. PracticeUpdate. Accessed December 1, 2021.
- Sledge GW, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875-2884.
- Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer in Premenopausal Women. PracticeUpdate. Accessed December 1, 2021.
- FDA approves abemaciclib with endocrine therapy for early breast cancer. Accessed December 1, 2021.
Disclosure statements are available on the authors' profiles: